Cargando…

Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review

Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival. However, we often encounter cases where treatment must be discontinued due to the occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyuki, Iwamoto, Hideki, Shimose, Shigeo, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Yamaguchi, Taizo, Nakano, Masahito, Kuromatsu, Ryoko, Koga, Hironori, Kawaguchi, Takumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355247/
https://www.ncbi.nlm.nih.gov/pubmed/35936693
http://dx.doi.org/10.3389/fonc.2022.948293
_version_ 1784763252353269760
author Suzuki, Hiroyuki
Iwamoto, Hideki
Shimose, Shigeo
Niizeki, Takashi
Shirono, Tomotake
Noda, Yu
Kamachi, Naoki
Yamaguchi, Taizo
Nakano, Masahito
Kuromatsu, Ryoko
Koga, Hironori
Kawaguchi, Takumi
author_facet Suzuki, Hiroyuki
Iwamoto, Hideki
Shimose, Shigeo
Niizeki, Takashi
Shirono, Tomotake
Noda, Yu
Kamachi, Naoki
Yamaguchi, Taizo
Nakano, Masahito
Kuromatsu, Ryoko
Koga, Hironori
Kawaguchi, Takumi
author_sort Suzuki, Hiroyuki
collection PubMed
description Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival. However, we often encounter cases where treatment must be discontinued due to the occurrence of adverse events. One of these events, which is often fatal, is gastrointestinal bleeding. To clarify the clinical effects of gastrointestinal bleeding after AB treatment, we evaluated patients with HCC who were treated with AB at our institution. Of the 105 patients, five treated with AB developed gastrointestinal bleeding, necessitating treatment discontinuation. Additionally, we encountered two cases where exacerbation of varicose veins was observed, and AB therapy could be continued by preventive treatment of varices. In conclusion, an appropriate follow-up is required during treatment with AB to prevent possible exacerbation of varicose veins.
format Online
Article
Text
id pubmed-9355247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93552472022-08-06 Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review Suzuki, Hiroyuki Iwamoto, Hideki Shimose, Shigeo Niizeki, Takashi Shirono, Tomotake Noda, Yu Kamachi, Naoki Yamaguchi, Taizo Nakano, Masahito Kuromatsu, Ryoko Koga, Hironori Kawaguchi, Takumi Front Oncol Oncology Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival. However, we often encounter cases where treatment must be discontinued due to the occurrence of adverse events. One of these events, which is often fatal, is gastrointestinal bleeding. To clarify the clinical effects of gastrointestinal bleeding after AB treatment, we evaluated patients with HCC who were treated with AB at our institution. Of the 105 patients, five treated with AB developed gastrointestinal bleeding, necessitating treatment discontinuation. Additionally, we encountered two cases where exacerbation of varicose veins was observed, and AB therapy could be continued by preventive treatment of varices. In conclusion, an appropriate follow-up is required during treatment with AB to prevent possible exacerbation of varicose veins. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9355247/ /pubmed/35936693 http://dx.doi.org/10.3389/fonc.2022.948293 Text en Copyright © 2022 Suzuki, Iwamoto, Shimose, Niizeki, Shirono, Noda, Kamachi, Yamaguchi, Nakano, Kuromatsu, Koga and Kawaguchi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Suzuki, Hiroyuki
Iwamoto, Hideki
Shimose, Shigeo
Niizeki, Takashi
Shirono, Tomotake
Noda, Yu
Kamachi, Naoki
Yamaguchi, Taizo
Nakano, Masahito
Kuromatsu, Ryoko
Koga, Hironori
Kawaguchi, Takumi
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title_full Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title_fullStr Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title_full_unstemmed Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title_short Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
title_sort case report: exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: a case series and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355247/
https://www.ncbi.nlm.nih.gov/pubmed/35936693
http://dx.doi.org/10.3389/fonc.2022.948293
work_keys_str_mv AT suzukihiroyuki casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT iwamotohideki casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT shimoseshigeo casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT niizekitakashi casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT shironotomotake casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT nodayu casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT kamachinaoki casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT yamaguchitaizo casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT nakanomasahito casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT kuromatsuryoko casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT kogahironori casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview
AT kawaguchitakumi casereportexacerbationofvaricesfollowingatezolizumabplusbevacizumabtreatmentofhepatocellularcarcinomaacaseseriesandliteraturereview